Abstracts tagged "corticosteroids"

Abstract Number: 0466 • ACR Convergence 2020
Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic
Marianna Frey¹, Gregory Vitone², Candace Feldman³, Lindsay Lally¹, Anne Bass⁴, Jane Salmon¹, Mary Crow¹, Michael Lockshin⁵, Vivian Bykerk¹, Lisa Mandl¹ and Medha Barbhaiya⁵, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Brigham and Women's Hospital, Boston, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases living in COVID-19 “hot spots” may have modified their immunomodulatory…
Abstract Number: 0872 • ACR Convergence 2020
Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia
Ilze Vinkalna¹, Inita Bulina², Natalija Vellere², Kristine Ivanova², Pauls Rubins², Renate Diura², Santa Mikena², Julija Zepa² and Daina Andersone², ¹Pauls Stradins Clinical University Hospital, Rīga, Latvia, ²Pauls Stradins Clinical University Hospital, Riga
Background/Purpose: To determine the factors influencing hospitalisation duration, re – hospitalisation (more than 1 hospitalisation during the study period), frequency of the usage of corticosteroids…
Abstract Number: 1014 • ACR Convergence 2020
Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years
John Hanly¹ and Lynn Lethbridge², ¹Dalhousie University, Halifax, NS, Canada, ²Dalhousie University, Halifax, Canada
Background/Purpose: The objective of the current study was to examine the change in prescribing patterns for older adults with RA over a 20 year period…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: 1571 • ACR Convergence 2020
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
Sang Kim¹, Jean Tayar², Maria Suarez-Almazor³, Huifang Lu⁴, Yang-Zhi Zhao⁵, Margarita Divenko⁵, William Padron⁵, Emma Rodriguez⁵, Sattva Neelapu⁵, Jennifer Wang⁵, Amish Shah⁵, Nizar Tannir⁵, Don Gibbons⁵, Guillermo Garcia-Manero⁵, Hussein Tawbi⁵, Patrick Hwu⁵, Andrew Futreal⁵, Adi Diab⁵ and Roza Nurieva⁵, ¹The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas MD Anderson Cancer Center, Houston, TX, ⁴MD Anderson, Houston, TX, ⁵MD Anderson, Houston
Background/Purpose: Despite of unprecedented clinical success in cancer therapeutics, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Arthritis-irAE can…
Abstract Number: 029 • 2020 Pediatric Rheumatology Symposium
Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis
Angela Chun¹, Lutfiyya Muhammad ² and Deirdre De Ranieri ³, ¹Lurie Children's Hospital, Chicago, Iowa, ²Northwestern University Feinberg School of Medicine, Chicago, ³Lurie Children's Hospital, Chicago, Illinois
Background/Purpose: The use of intra-articular corticosteroid (IAC) injections for Juvenile Idiopathic Arthritis (JIA) was extrapolated from its use in adult inflammatory joint diseases to achieve…
Abstract Number: 067 • 2020 Pediatric Rheumatology Symposium
Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis
Rana Masoud¹, Wajiha Jeelani ², Barbine Agbor Agbor ³, Teresa Hennon ², Brian Wrotniak ⁴ and Rabheh Abdul Aziz ², ¹Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, New York, ²Department of Pediatric Rheumatology, University at Buffalo, Oishei Children's Hospital, Buffalo, ³Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, ⁴Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, NY, USA, Buffalo
Background/Purpose: Oligo-articular juvenile idiopathic arthritis (Oligo JIA) is the most common subtype of juvenile idiopathic arthritis. Intra-articular corticosteroid (IAC) injection is a mainstay treatment of…
Abstract Number: 092 • 2020 Pediatric Rheumatology Symposium
The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries
Mary Beth Son¹, Yukiko Kimura ², Kristiina Aalto ³, Lillemor Berntson ⁴, Johnathan Dallas ¹, Ciaran Duffy ⁵, Mia Glerup ⁶, Jaime Guzman ⁷, Troels Herlin ⁸, Petteri Hovi ⁹, Kimme Hyrich ¹⁰, Jens Klotsche ¹¹, Bo Magnusson ¹², Vanessa McIntyre ¹³, Ellen Nordal ¹⁴, Seza Ozen ¹⁵, Maria Jose Santos ¹⁶, Betul Sozeri ¹⁷ and Timothy Beukelman ¹⁸, ¹Boston Children's Hospital, Boston, Massachusetts, ²Hackensack Meridian School of Medicine, Hackensack, ³Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁴Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ⁵Ottawa, Canada, ⁶Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁷University of British Columbia and BC Children's Hospital, Vancouver, Canada, ⁸Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰Manchester, United Kingdom, ¹¹Berlin, Germany, ¹²Karolinska University Hospital, Stockholm, Sweden, ¹³Manchester University, Manchester UK, United Kingdom, ¹⁴Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ¹⁵Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, ¹⁶Portugal, ¹⁷Boston, Turkey, ¹⁸University of Alabama at Birmingham, Birmingham
Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries…
Abstract Number: 119 • 2020 Pediatric Rheumatology Symposium
Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database
Takayuki Kishi¹, Takako Miyamae ², Ryoko Sakai ³, Yumi Tani ², Satoru Nagata ¹ and Masayoshi Harigai ³, ¹Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ²Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Background: Immunosuppressive therapy is the mainstay of treatment of child systemic lupus erythematosus (cSLE). However until very recently, the treatment of cSLE lacked uniformity.…
Abstract Number: 175 • 2020 Pediatric Rheumatology Symposium
Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration
Erin Balay¹, Jennifer Weiss ², Y. Ingrid Goh ³, Nathan Rubin ⁴ and Danielle Bullock ⁴, ¹University of Minnesota, saint paul, ²Hackensack University Medical Center, Hackensack, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of Minnesota, Minneapolis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood disease which can result in debilitating arthritis. The 2011 ACR JIA treatment guidelines recommend intra-articular corticosteroid…
Abstract Number: 2068 • 2019 ACR/ARP Annual Meeting
Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications
Vivian Bykerk¹, Andrew Blauvelt ², Jeffrey Curtis ³, Cécile Gaujoux-Viala ⁴, Tore K. Kvien ⁵, William J. Sandborn ⁶, Kevin Winthrop ⁷, Christina Popova ⁸ and Xavier Mariette ⁹, ¹Hospital for Special Surgery, New York City, NY, ²Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Nîmes University Hospital, Nîmes, France, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶University of California, La Jolla, CA, ⁷Oregon Health and Science University, Portland, OR, ⁸UCB Pharma, Brussels, Belgium, ⁹Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: Certolizumab pegol (CZP) is an anti-TNF drug approved for rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn’s disease (CD).…
Abstract Number: 2114 • 2019 ACR/ARP Annual Meeting
Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases
Daisuke Kobayashi¹, Sayuri Takamura ², Yoko Wada ³, Takeshi Kuroda ⁴ and Ichiei Narita ¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, ³Niigata Rinko Hospital, Niigata, Niigata, Japan, ⁴Health administration office, Niigata University, Niigata, Niigata, Japan
Background/Purpose: Intensive immunosuppressive treatment is often required for patients with autoimmune diseases, and those who are thus treated have a high risk of opportunistic infections.…
Abstract Number: 2784 • 2019 ACR/ARP Annual Meeting
Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients
Melissa E. Munroe¹, Carla J. Guthridge ¹, Sarah Kleckner ¹, Ly Tran ², Joel Guthridge ³, Debra J. Zack ⁴, Judith James ³ and Joan T. Merrill ⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Xencor, Inc., San Diego, CA, ⁵Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is typified by a wide spectrum of clinical manifestations and immune dysregulation. Corticosteroids are almost universally effective, but marked by unacceptable side effects.…
Abstract Number: 273 • 2019 ACR/ARP Annual Meeting
Bone Health in Lupus: Findings from the Southern California Lupus Registry
Vaneet Sandhu, MBBS¹ and Sara Johnson ², ¹Loma Linda University, Loma Linda, CA, ²St George's University, Loma Linda, CA
Background/Purpose: The association of vitamin D deficiency with SLE is well established. While disease activity can itself cause pathologic bone remodeling and reduced vitamin D,…
Abstract Number: 858 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE
Saira Sheikh¹, Morton Scheinberg ², Cheng-Chung Wei ³, Dana Tegzova ⁴, William Stohl ⁵, Ricardo Acayaba de Toledo ⁶, Tamara Mucenic ⁷, Mauricio Abello Banfi ⁸, Kathleen Maksimowicz-McKinnon ⁹, Carlos Abud-Mendoza ¹⁰, Sandra Navarra ¹¹, Mercedes Garcia ¹², Ignacio Garcia-De La Torre ¹³, Josep Ordi Ros ¹⁴, Roger Abramino Levy ¹⁵, Damon L Bass ¹⁵, Jorge Ross Terrés ¹⁶, Raj Punwaney ¹⁶, Julia Harris ¹⁷, Alireza Nami ¹⁸, Amy Pierce ¹⁹, Kevin Thorneloe ²⁰, Beulah Ji ¹⁷ and David Roth ¹⁶, ¹University of North Carolina, Chapel Hill, NC, ²Centro de Pesquisas Clinicas do Hospital Abreu Sodré, São Paulo, Brazil, ³Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ⁴Institute of Rheumatology, Prague, Czech Republic, ⁵University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil, ⁷Hospital Moinhos Angeles de Vento, Porto Alegre, Brazil, ⁸Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁹Henry Ford Hospital, Wayne State University, Detroit, MI, ¹⁰Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatologia y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico, ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²Hospital San Martín, La Plata, Argentina, ¹³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Jalisco, Mexico, ¹⁴Hospital Vall d'Hebron, Barcelona, Spain, ¹⁵GlaxoSmithKline, Collegeville, PA, ¹⁶GSK, Collegeville, PA, ¹⁷GSK, Uxbridge, Middlesex, United Kingdom, ¹⁸Joint Muscle Medical Care and Research Institute, Charlotte, NC, ¹⁹ViiV Healthcare, Research Triangle Park, NC, ²⁰GSK, Collegeville, NC
Background/Purpose: Belimumab (BEL), approved in active, autoantibody-positive SLE, has demonstrated a positive efficacy/safety profile while suggesting potential for steroid sparing and reduced organ damage accrual.…

« Previous Page
1
…
5
6
7
8
9
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].